Conavi Medical Corp. Announces Pricing of Public Offering of Common Shares and/or Pre-Funded Warrants

Core Viewpoint - Conavi Medical Corp. is conducting a public offering of common shares and pre-funded common share purchase warrants to raise between $15 million and $20 million for the development of its Novasight Hybrid system and general corporate purposes [2][3][4]. Offering Details - The offering consists of a minimum of 33,333,333 and a maximum of 44,444,444 securities priced at $0.45 per common share or $0.44999 per pre-funded warrant [3]. - Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.00001, with no expiration and can be exercised on a cashless basis [3]. Use of Proceeds - The net proceeds will be used to obtain US FDA 510(k) clearance for the Novasight Hybrid system, complete a limited market release, and initiate a broader commercial launch in the U.S. [4]. Closing and Regulatory Compliance - The offering is expected to close on or about December 23, 2025, subject to customary closing conditions and regulatory approvals [6]. - A final short form prospectus will be filed with securities regulatory authorities in Alberta, British Columbia, and Ontario [5]. Agent and Fees - The company will pay the agent a cash fee of 6.5% of the gross proceeds and grant compensation options equal to 6.5% of the total number of securities issued [7]. - A reduced cash commission of 3.25% will apply to certain purchasers on a president's list [7]. Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures, with its Novasight Hybrid system combining intravascular ultrasound and optical coherence tomography [12].